Focus is on Zydus Lifesciences Shares Following FDA Clearance of A Medication for Prostate Cancer
On Tuesday, March 18, pharmaceutical manufacturer Zydus Lifesciences Ltd. said that the (FDA) had permitted it to produce and purchase 60 mg of apalutamide, the generic version of 60 mg Erleada tablets. Patients with metastatic castration-sensitive prostate cancer may benefit from therapy with the androgen receptor inhibitor palutamide. At Zydus Lifesciences Ltd (SEZ), Ahmedabad, apalutamide…